Psychobiological effects of prenatal glucocorticoid exposure in 10-year-old-children

Katja Erni1, Luljeta Shaqiri-Emini, Roberto La Marca

  • 1Department of Clinical Psychology and Psychotherapy, Psychological Institute, University of Zurich Zurich, Switzerland ; Department of Obstetrics, University Hospital Zurich Zurich, Switzerland.

Frontiers in Psychiatry
|December 13, 2012
PubMed

Insights

Prenatal exposure to glucocorticoids in children affects their stress appraisal and cortisol levels during a psychosocial stress test. These findings highlight long-term psychobiological impacts of maternal treatment during pregnancy.

Area of Science:

  • Developmental Psychology
  • Endocrinology
  • Neuroscience

Background:

  • Prenatal stress can have lasting effects on offspring.
  • Limited research exists on prenatal glucocorticoid exposure's impact on children's stress responses.

Purpose of the Study:

  • To investigate the effects of prenatal glucocorticoid exposure on psychological, endocrine, and autonomic stress responses in children.

Main Methods:

  • 115 ten-year-old children were studied.
  • Groups included children exposed to glucocorticoids+tocolytics, tocolytics only, and a control group.
  • Psychological parameters, salivary cortisol, salivary alpha-amylase, and heart rate were measured during the Trier Social Stress Test for Children.

Main Results:

  • Children prenatally exposed to glucocorticoids showed significantly different control expectancies (stress appraisal) compared to controls.
  • Significant differences in salivary cortisol levels were observed between groups.
  • Trends toward significance were noted for overall stress appraisal and heart rate.

Conclusions:

  • Prenatal maternal glucocorticoid exposure is associated with altered psychobiological stress reactivity in ten-year-old children.
  • These findings suggest a lasting impact of prenatal glucocorticoid exposure on stress response systems.
Abstract

Related Concept Videos

Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...
Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...